Clinical and Translational Oncology

, Volume 17, Issue 1, pp 65–73

Expression of vimentin and survivin in clear cell renal cell carcinoma and correlation with p53

  • Z.-G. Shi
  • S.-Q. Li
  • Z.-J. Li
  • X.-J. Zhu
  • P. Xu
  • G. Liu
Research Article



This study focuses on investigating the expression correlation of vimentin, survivin and p53 in clear cell renal cell carcinoma (ccRCC) and the clinical significance.


The mRNA and protein expression levels of the vimentin, survivin and p53 were determined in ccRCC and adjacent normal renal tissues, using quantitative real-time-polymerase chain reaction (qRT-PCR) and Western blot. We detected the expression and localization of vimentin, survivin and p53 protein in ccRCC by immunohistochemistrical SP method and analyzed the relationships among clinical pathologic parameters and patient prognosis.


The expression of vimentin and survivin was significantly increased in ccRCC compared with adjacent normal renal tissues, which were positively correlated with the pathological grade and clinical stage (P < 0.05). p53 was highly expressed in ccRCC compared with normal tissues (P < 0.05), which was not positively correlated with the pathological grade and clinical stage (P > 0.05). Furthermore, univariate and multivariate analysis showed that high expression levels of vimentin and survivin were independent prognostic indicators for ccRCC. The levels of vimentin and survivin were positively correlated in ccRCC (r = 0.428, P < 0.01).


Reliable basis about biological behavior and prognosis judgments of ccRCC can be provided by combining detection of vimentin and survivin. Foundation and new ideas for gene therapy of ccRCC may be provided by further studying the relationship among vimentin, survivin and p53 in ccRCC.


Vimentin Survivin ccRCC p53 Relationship 


  1. 1.
    Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373:1119–32.PubMedCrossRefGoogle Scholar
  2. 2.
    Klatte T, Pantuck AJ, Kleid MD, Belldegrun AS. Understanding the natural biology of kidney cancer: implications for targeted cancer therapy. Rev Urol. 2007;9:47–56.PubMedCentralPubMedGoogle Scholar
  3. 3.
    Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353:2477–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Schopferer M, Bär H, Hochstein B, Sharma S, Mücke N, Herrmann H, et al. Desmin and vimentin intermediate filament networks: their viscoelastic properties investigated by mechanical rheometry. J Mol Biol. 2009;388:133–43.PubMedCrossRefGoogle Scholar
  5. 5.
    Shirahata A, Sakata M, Sakuraba K, Goto T, Mizukami H, Saito M, et al. Vimentin methylation as a marker for advanced colorectal carcinoma. Anticancer Res. 2009;29:279–81.PubMedGoogle Scholar
  6. 6.
    Moustakas A, Heldin CH. Signaling networks guiding epithelial–mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007;98:1512–20.PubMedCrossRefGoogle Scholar
  7. 7.
    Perlson E, Michaelevski I, Kowalsman N, Ben-Yaakov K, Shaked M, Seger R, et al. Vimentin binding to phosphorylated Erk sterically hinders enzymatic dephosphorylation of the kinase. J Mol Biol. 2006;364:938–44.PubMedCrossRefGoogle Scholar
  8. 8.
    Derynck R, Akhurst RJ. Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat Cell Biol. 2007;9:1000–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Thiery JP, Sleeman JP. Complex networks orchestrate epithelial–mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–42.PubMedCrossRefGoogle Scholar
  10. 10.
    Chang L, Goldman RD. Intermediate filaments mediate cytoskeletal crosstalk. Nat Rev Mol Cell Biol. 2004;5:601–13.PubMedCrossRefGoogle Scholar
  11. 11.
    Dean EJ, Ranson M, Blackhall F, Dive C. X-linked inhibitor of apoptosis protein as a therapeutic target. Expert Opin Ther Targets. 2007;11:1459–71.PubMedCrossRefGoogle Scholar
  12. 12.
    Oto OA, Paydas S, Tanriverdi K, Seydaoglu G, Yavuz S, Disel U. Survivin and EPR-1 expression in acute leukemias: prognostic significance and review of the literature. Leuk Res. 2007;31:1495–501.PubMedCrossRefGoogle Scholar
  13. 13.
    Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2010;2:a001107.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Goldstein I, Marcel V, Olivier M, Oren M, Rotter V, Hainaut P. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther. 2011;18:2–11.PubMedCrossRefGoogle Scholar
  15. 15.
    Vousden KN, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2007;8:275–83.PubMedCrossRefGoogle Scholar
  16. 16.
    Yang X, Wang J, Liu C, Grizzle WE, Yu S, Zhang S, et al. Cleavage of p53-vimentin complex enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of rheumatoid arthritis synovial fibroblasts. Am J Pathol. 2005;167:705–19.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutation in human cancers. Science. 1991;253:49–53.PubMedCrossRefGoogle Scholar
  18. 18.
    Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M, et al. The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer. 1994;69:409–16.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Mohammed A, Shergill I, Little B. Management of metastatic renal cell carcinoma: current trends. Expert Rev Mol Diagn. 2009;9:75–83.PubMedCrossRefGoogle Scholar
  20. 20.
    Liu T, Zhang X, Shang M, Zhang Y, Xia B, Niu M, et al. Dysregulated expression of Slug, vimentin, and E-cadherin correlates with poor clinical outcome in patients with basal like breast cancer. J Surg Oncol. 2013;107:188–94.PubMedCrossRefGoogle Scholar
  21. 21.
    Yao X, Wang X, Wang Z, Dai L, Zhang G, Yan Q, et al. Clinicopathological and prognostic significance of epithelial mesencymal transition-related protein expression in intrahepatic cholangiocarcinoma. Onco Targets Ther. 2012;5:255–61.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Al-Saad S, Al-Shibli K, Donnem T, Persson M, Bremnes RM, Busund LT. The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. Br J Cancer. 2008;99:1467–83.CrossRefGoogle Scholar
  23. 23.
    Zhao Y, Yan Q, Long X, Chen X, Wang Y. Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem Funct. 2008;26:571–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Hwa JS, Park HJ, Jung JH, Kam SC, Park HC, Kim CW, et al. Identification of proteins differentially exrpressed in the conventional renal cell carcinoma by proteomic analysis. J Korean Med Sci. 2005;20:450–5.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Williams AA, Higgins JP, Zhao H, Ljunberg B, Brooks JD. CD9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma. BMC Clin Pathol. 2009;9:9.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Hsu KF, Lin CK, Yu CP, Tzao C, Lee SC, Lee YY, et al. Cortactin, fascin, and survivin expression associated with clinicopathological parameters in esophageal squamous cell carcinoma. Dis Esophagus. 2009;22:402–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer. 2007;109:1106–13.PubMedCrossRefGoogle Scholar
  28. 28.
    Wang GC, Hsieh PS, Hsu HH, Sun GH, Nieh S, Yu CP, et al. Expression of cortactin and survivin in renal cell carcinoma associated with tumor aggressiveness. World J Urol. 2009;27:557–63.PubMedCrossRefGoogle Scholar
  29. 29.
    Andersen MH, Svane IM, Becker JC, Straten PT. The universal character of the tumor-associated antigen survivin. Clin Cancer Res. 2007;13:5991–4.PubMedCrossRefGoogle Scholar
  30. 30.
    Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, et al. Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer. 2011;10:188–93.PubMedCrossRefGoogle Scholar
  31. 31.
    Hsu YF, Sheu JR, Lin CH, Yang DS, Hsiao G, Ou G, et al. Trichostatin A and sirtinol suppressed survivin expression through AMPK and p38MAPK in HT29 colon cancer cells. Biochim Biophys Acta. 2012;1820:104–15.PubMedCrossRefGoogle Scholar
  32. 32.
    Masuda A, Kamai T, Abe H, Arai K, Yoshida K. Is Stat3 and/or p53 mRNA expression a prognostic marker for renal cell carcinoma? Biomed Res. 2009;30:171–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Zubac DP, Bostad L, Kihl B, Seidal T, Wentzel-Larsen T, Haukaas SA. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival. J Urol. 2009;182:2144–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 2002;21:2613–22.PubMedCrossRefGoogle Scholar
  35. 35.
    Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002;277:3247–57.PubMedCrossRefGoogle Scholar
  36. 36.
    Lynch CJ, Milner J. Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: a basis for p53 haplo-insufficiency. Oncogene. 2006;25:3463–70.PubMedCrossRefGoogle Scholar
  37. 37.
    Vegran F, Boidot R, Oudin C, Riedinger JM, Lizard-Nacol S. Distinct expression of survivin splice vaiants in breast carcinomas. Int J Oncol. 2005;27:1151–7.PubMedGoogle Scholar
  38. 38.
    Kar R, Sen S, Singh A, Sharma H, Kumar S, Gupta SD, et al. Role of apoptotic regulators in human epithelial ovarian cancer. Cancer Biol Ther. 2007;6:1101–5.PubMedCrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2014

Authors and Affiliations

  • Z.-G. Shi
    • 1
  • S.-Q. Li
    • 2
  • Z.-J. Li
    • 1
  • X.-J. Zhu
    • 1
  • P. Xu
    • 1
  • G. Liu
    • 1
  1. 1.Department of UrologyThe First Affiliated Hospital of Henan University of Science and TechnologyLuoyangPeople’s Republic of China
  2. 2.Molecular Medicine Key Laboratory of Liver Injury and Repair, Medical CollegeHenan University of Science and TechnologyLuoyangPeople’s Republic of China

Personalised recommendations